Invention Grant
- Patent Title: Chemical compounds
- Patent Title (中): 化合物
-
Application No.: US13130368Application Date: 2009-11-18
-
Publication No.: US08697685B2Publication Date: 2014-04-15
- Inventor: Jeffrey Michael Axten , Charles William Blackledge, Jr. , Gerald Patrick Brady, Jr. , Yanhong Feng , Seth W. Grant , Jesus Raul Medina , William H. Miller , Stuart P. Romeril
- Applicant: Jeffrey Michael Axten , Charles William Blackledge, Jr. , Gerald Patrick Brady, Jr. , Yanhong Feng , Seth W. Grant , Jesus Raul Medina , William H. Miller , Stuart P. Romeril
- Applicant Address: US DE Wilmington
- Assignee: GlaxoSmithKline LLC
- Current Assignee: GlaxoSmithKline LLC
- Current Assignee Address: US DE Wilmington
- Agent Andrea V. Lockenour; Edward R. Gimmi; Carl W. Battle
- International Application: PCT/US2009/064891 WO 20091118
- International Announcement: WO2010/059658 WO 20100527
- Main IPC: A61K31/33
- IPC: A61K31/33 ; A61K31/54 ; A61K31/505 ; A61K31/55 ; C07D401/08 ; C07D417/02 ; C07D413/06 ; C07D239/02
Abstract:
The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
Public/Granted literature
- US20110275611A1 CHEMICAL COMPOUNDS Public/Granted day:2011-11-10
Information query
